These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 33692246)

  • 21. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Thyrotropin-secreting pituitary adenomas].
    Caron P
    Presse Med; 2009 Jan; 38(1):107-11. PubMed ID: 18980829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
    Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
    J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs.
    Rabbiosi S; Peroni E; Tronconi GM; Chiumello G; Losa M; Weber G
    Thyroid; 2012 Oct; 22(10):1076-9. PubMed ID: 22947349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
    Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A
    Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Medical treatment of pituitary adenoma].
    Chanson P
    Rev Prat; 1996 Jun; 46(12):1509-13. PubMed ID: 8881166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
    Neggers SJ; Pronin V; Balcere I; Lee MK; Rozhinskaya L; Bronstein MD; Gadelha MR; Maisonobe P; Sert C; van der Lely AJ;
    Eur J Endocrinol; 2015 Sep; 173(3):313-23. PubMed ID: 26047625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
    Zhang CF; Liang D; Zhong LY
    Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and morphological characteristics, diagnostic criteria, and outcomes of surgical treatment of TSH-secreting pituitary adenomas.
    Astaf'eva LI; Kadashev BA; Shishkina LV; Kalinin PL; Fomichev DV; Kutin MA; Aref'eva IA; Dzeranova LK; Sidneva YG; Klochkova IS; Rotin DL
    Zh Vopr Neirokhir Im N N Burdenko; 2016; 80(6):24-35. PubMed ID: 28139570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical management of thyrotropin-secreting pituitary adenomas.
    Beck-Peccoz P; Persani L
    Pituitary; 2002; 5(2):83-8. PubMed ID: 12675505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
    Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of TSH-secreting pituitary adenoma with cyclic fluctuations in serum TSH levels.
    Okuma H; Hashimoto K; Ohashi T; Mihara M; Minami I; Izumiyama H; Sasaki S; Inoshita N; Nishioka H; Yamada S; Yoshimoto T
    Endocr J; 2018 Jul; 65(7):737-746. PubMed ID: 29695647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics and response cutoff of octreotide suppression test in thyrotrophin (TSH)-secreting pituitary adenomas.
    Liu J; Yang Y; Duan L; Chai X; Zhu H; Deng K; Lian X; Yao Y
    Clin Endocrinol (Oxf); 2023 Sep; 99(3):306-314. PubMed ID: 37144621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.
    Mao ZG; Zhu YH; Tang HL; Wang DY; Zhou J; He DS; Lan H; Luo BN; Wang HJ
    Eur J Endocrinol; 2010 Apr; 162(4):661-6. PubMed ID: 20061334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment.
    Boix E; López P; Pérez-Mateo M; Picó A
    J Endocrinol Invest; 2004 Jun; 27(6):613-4. PubMed ID: 15717663
    [No Abstract]   [Full Text] [Related]  

  • 38. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients].
    Trukhina DA; Przhiyalkovskaya EG; Belaya ZE; Grigoriev AY; Azizyan VN; Mamedova EO; Rozhinskaya LY; Lapshina AM; Pigarova EA; Dzeranova LK; Platonova NM; Troshina EA; Melnichenko GA
    Probl Endokrinol (Mosk); 2023 Sep; 70(2):23-36. PubMed ID: 38796758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].
    Zieliński G; Podgórski JK; Koziarski A; Siwik J; Zgliczyński W; Wieliczko W
    Neurol Neurochir Pol; 2001; 35(3):423-37. PubMed ID: 11732266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.